Otlertuzumab
Otlertuzumab, also known as TRU-016, is a humanized monoclonal antibody that binds to CD37, a protein found on some cancer cells. It is being developed as a cancer treatment and has been studied in clinical trials for lymphoma and chronic lymphocytic leukemia (CLL). It was developed by Emergent BioSolutions.
This page was last edited on 2 February 2026, at 11:58 (CET).